Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Update: FDA Panel Supports Approval Of Valeant’s Psoriasis Drug With Risk Management

XTALKS VITALS NEWS

FDA

While the FDA has not officially approved the drug, the agency usually follows the advice of the advisory panel.

Tweetables from this article:

Tweet: #FDA: Valeant’s #psoriasis drug should be approved, along with measures designed to reduce the risk of suicide http://ctt.ec/37Kef+FDA: Valeant’s psoriasis drug should be approved, along with measures designed to reduce the risk of suicide.

Tweet: Valeant has proposed a risk management registry for #psoriasis drug, but is not in favour of a boxed warning http://ctt.ec/IJu30+Valeant has proposed a risk management registry for psoriasis drug, but is not in favour of a boxed warning.

Share this!

July 21, 2016 | by Sarah Massey, M.Sc.

An advisory committee to the US Food and Drug Administration (FDA) has concluded that Valeant Pharmaceuticals’ experimental psoriasis drug should be approved, along with measures designed to reduce the risk of suicide. While the FDA has not officially approved the drug, the agency usually follows the advice of the advisory panel.

In all, six patients committed suicide across multiple clinical trials for the psoriasis drug, brodalumab. Four of the suicides took place during psoriasis clinical trials, with one in a psoriatic arthritis study and one in a rheumatoid arthritis study. Despite the deaths, the FDA advisory committee voted unanimously to approve the drug.

The majority of panel members voted that the drug should be prescribed in conjunction with a suicide risk management program. This program could include communications plans for healthcare providers as well as medication guides.



The advisory panel noted that the risks of brodalumab were outweighed by the potential benefits of the drug, which could offer a new treatment option for psoriasis sufferers. A boxed warning and a patient data registry were also proposed as ways to mitigate the suicide risk.

While some thought the registry should be mandatory for all patients, other members were concerned that this could create barriers to patient access to the drug. Valeant has proposed a risk management registry, but is not in favour of a boxed warning.

Brodalumab is an interleukin-17 receptor antagonist, designed to reduce inflammation. Novartis’ Cosentyx and Eli Lilly’s Taltz, are currently available drugs from this class.

According to the American Academy of Dermatology, approximately 7.5 million US citizens suffer from psoriasis. The autoimmune disease is characterized by scaly patches of dry skin, which sometimes occurs in people with diabetes and heart disease.


Keywords: FDA, Psoriasis, Boxed Warning


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.